RxDoctor Payments Data

Carolyn Glazer-Hockstein, MD

Ophthalmology · Wilmington, DENPI 1881694156

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $182, 4.6 times the $40 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in DE, where the typical reported total is $1,099.

$298in general payments, 2019–2025

Across 14 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$51
  • Genentech USA, Inc.$48
  • Harrow Eye, LLC$45
  • Novartis$40
  • Apellis Pharmaceuticals, Inc.$25
  • Alcon$25
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$298 in reported general payments places this provider in the 20th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$2,571,310
Medicare patients
676
Services billed
35,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine12$8,438
SimbrinzaBrinzolamide/Brimonidine Tart13$2,524
Prednisolone Acetate56$2,265
Latanoprost132$2,246
Ketorolac Tromethamine65$1,715
Diclofenac Sodium166$1,547
Brimonidine Tartrate30$1,524
Difluprednate12$1,316
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat19$376
Dorzolamide Hcl14$345
ErythromycinErythromycin Base26$226
Timolol Maleate18$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$22$8,43812 claims
AlconSimbrinza$25$2,52413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 49 ophthalmology providers in Delaware.

Other ophthalmology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →